Novus Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.12.20	Novus Therapeutics Appoints June Lee, M.D., to Board of Directors (Businesswire)
16.11.20	Novus Therapeutics Reports Third Quarter 2020 Financial Results (Businesswire)
10.11.20	Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16 (Businesswire)
02.11.20	Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis (Businesswire)
02.10.20	Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split (Businesswire)
17.09.20	Pre-market Movers In Healthcare Sector: SRNE, GNCA, VXRT, BNTX, INO... (RTTNews)
15.09.20	Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences (Businesswire)
15.09.20	Pre-market Movers In Healthcare Sector: NVUS, MRNS, ABIO, LPCN, CLRB, VXRT… (RTTNews)
14.09.20	Novus Therapeutics Announces Acquisition of Anelixis Therapeutics (Businesswire)
02.06.20	NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps (RTTNews)
01.06.20	Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media (Businesswire)
15.05.20	Novus Therapeutics Reports First Quarter 2020 Financial Results (Businesswire)
17.03.20	Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results (Businesswire)
02.03.20	Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media (Businesswire)
13.01.20	Novus Therapeutics Provides Update on OP0201 (Businesswire)
10.01.20	Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds (Businesswire)
29.11.19	Novus Therapeutics to Participate in Two Investor Conferences (Businesswire)
13.11.19	Novus Therapeutics Reports Third Quarter 2019 Financial Results (Businesswire)
29.10.19	Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion (Businesswire)
29.08.19	Novus Therapeutics to Participate in Two Upcoming Investor Conferences (Businesswire)
13.08.19	Novus Therapeutics Reports Second Quarter 2019 Financial Results (Businesswire)
10.06.19	Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media (Businesswire)
14.05.19	Novus Therapeutics Reports First Quarter 2019 Financial Results (Businesswire)
02.05.19	Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market (Businesswire)
30.04.19	Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market (Businesswire)
22.04.19	Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials (Businesswire)
28.03.19	Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates (Businesswire)
20.02.19	Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference (Businesswire)
19.02.19	Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 (Businesswire)
11.02.19	Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201 (Businesswire)
04.02.19	Best Of January: Biotech Stocks That Made Triple-digit Gains (RTTNews)
01.02.19	5 Top Gainers In Healthcare Sector (NVUS, MGTX, APHA...) (RTTNews)
30.01.19	Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials (Businesswire)
08.01.19	Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201 (Businesswire)
28.12.18	BTAI On Fast Track, ERYP Faces Busy Year Ahead, CHMA Turning Heads (RTTNews)
04.12.18	Novus Therapeutics Announces Formation of Scientific Advisory Board (Businesswire)
27.11.18	Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201 (Businesswire)
15.11.18	Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference (Businesswire)
13.11.18	Novus Therapeutics Reports Third Quarter 2018 Financial Results (Businesswire)
24.10.18	SELB Fails To Impress, NVUS Faces Busy Year Ahead, NTGN Down 43% This Month (RTTNews)
26.09.18	Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference (Businesswire)
07.09.18	Novus Therapeutics to Postpone Offering of Common Stock (Businesswire)
04.09.18	Novus Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
02.08.18	XENT Trims Revenue Outlook, CTXR On Watch, Busy Year Ahead For NLNK (RTTNews)
19.06.18	Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media (Businesswire)
23.05.18	In The Spotlight: Novus Therapeutics (RTTNews)
11.05.18	Novus Therapeutics Reports First Quarter 2018 Financial Results (Businesswire)
10.04.18	Ikonopedia to Introduce Enhanced Breast Ultrasound Reporting Module at SBI (PR Newswire)
02.04.18	Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update (Businesswire)
15.03.18	DXR Soars On Big Volume, RXII Gets Attention, Busy Q2 Awaits SNDX (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Novus Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten